Possible pathogenetic role of new cytokines in postmenopausal osteoporosis and changes during calcitonin plus calcium therapy

Basit Öğe Kaydı
dc.contributor.authorGür, A
dc.contributor.authorDenli, A
dc.contributor.authorNas, K
dc.contributor.authorCevik, R
dc.contributor.authorKarakoc, M
dc.contributor.authorSarac, AJ
dc.contributor.authorErdogan, F
dc.date.accessioned2024-04-24T16:00:04Z
dc.date.available2024-04-24T16:00:04Z
dc.date.issued2002
dc.departmentDicle Üniversitesien_US
dc.description.abstractThe present study was designed to test if the serum cytokines (interleukin, or IL-1beta, -2, -2r, -6, -6r, -8, and -10, and tumor necrosis factor alpha, or TNF-alpha) and osteocalcin levels were different between 50 osteoporotic and 30 postmenopausal nonosteoporotic women and to evaluate the efficacy of calcitonin therapy during 6 months on serum cytokines and osteocalcin levels in postmenopausal osteoporotic women. In our study, serum levels of osteocalcin, TNF-alpha, IL-2, and IL-8 were significantly higher in the patient group (P < 0.05), whereas serum levels of IL-10 and IL-6r were significantly lower in the patient group (P < 0.05). When analysed separately according to bone turnover, serum levels of IL-10 and IL-6r were significantly lower in the normal-turnover group (P < 0.05), and IL-2, IL-8, and TNF-alpha were significantly higher in the high-turnover group than in the control group (P < 0.05). Statistically significant improvement seemed to happen in the patients receiving calcitonin plus calcium therapy (P < 0.05) concerning levels of serum IL-6r at the 1st month (P < 0.05), IL- 10, IL-2r, IL-6r, and osteocalcin at the 3rd month, and IL-6r and osteocalcin at the end of the 6th month. Our findings demonstrate that calcitonin plus calcium therapy appears to be particularly more effective for patients with high turnover. In addition, our study suggests that IL-10 and IL-6r may have an important role in normal-turnover osteoporosis, while IL-2, IL-8, and TNF-alpha may play an important role in high-turnover postmenopausal osteoporosis.en_US
dc.identifier.doi10.1007/s00296-002-0223-x
dc.identifier.endpage198en_US
dc.identifier.issn0172-8172
dc.identifier.issue5en_US
dc.identifier.pmid12215865
dc.identifier.scopus2-s2.0-0036041033
dc.identifier.scopusqualityQ1
dc.identifier.startpage194en_US
dc.identifier.urihttps://doi.org/10.1007/s00296-002-0223-x
dc.identifier.urihttps://hdl.handle.net/11468/14359
dc.identifier.volume22en_US
dc.identifier.wosWOS:000178492800006
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSpringer-Verlagen_US
dc.relation.ispartofRheumatology International
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCalcitoninen_US
dc.subjectCalciumen_US
dc.subjectCytokinesen_US
dc.subjectOsteocalcinen_US
dc.subjectPostmenopausal Osteoporosisen_US
dc.titlePossible pathogenetic role of new cytokines in postmenopausal osteoporosis and changes during calcitonin plus calcium therapyen_US
dc.titlePossible pathogenetic role of new cytokines in postmenopausal osteoporosis and changes during calcitonin plus calcium therapy
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu